Danish pharmaceutical giant Novo Nordisk on Tuesday named its new CEO and cut its full-year sales and profit guidance.

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Maziar Mike Doustdar spent more than three decades quietly climbing the ranks of Novo Nordisk A/S, from office clerk through ...

Novo Nordisk announced company veteran Maziar Mike Doustdar as its next CEO, as the firm struggles to regain its dominance in ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Danish leader will face a challenging landscape among competitors ...

Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...

Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...

Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief ...

Novo Nordisk, a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine ...

Discover the latest Wall Street trends: market declines, Q2 earnings highlights, and key stock moves from Tesla, Meta, Microsoft, and more.